Advertisement
U.S. markets open in 2 hours 48 minutes

Arcturus Therapeutics Holdings Inc. (ARCT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
39.73+0.97 (+2.50%)
At close: 04:00PM EST
39.00 -0.73 (-1.84%)
Pre-Market: 04:00AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close38.76
Open38.82
Bid37.00 x 800
Ask47.00 x 900
Day's Range38.77 - 40.48
52 Week Range14.21 - 43.81
Volume589,832
Avg. Volume409,030
Market Cap1.062B
Beta (5Y Monthly)2.64
PE Ratio (TTM)10.57
EPS (TTM)3.76
Earnings DateMar 07, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
15% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ARCT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Arcturus Therapeutics Holdings
    Daily – Vickers Top Buyers & Sellers for 11/29/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • InvestorPlace

    7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff

    While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet. To mitigate the downside risks, it may be better to consider undervalued enterprises. Of course, specifically targeting biotech stocks that trade below their intrinsic or perceived value offers no guarantee of success. Still, given the sometimes extreme mobility that the ecosystem facilitates, it may pa

  • Business Wire

    Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

    SAN DIEGO, February 26, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at a Fireside Chat hosted by Barclays 26th Annual Global Healthcare Conference in Miami, on Thursday, March 14, 2024, at 11:45 a.m. Eastern Time.

  • Business Wire

    Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis

    SAN DIEGO, February 22, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced that the European Commission (EC), based on a positive opinion issued by the European Medicines Agency (EMA), has granted orphan medicinal product designation for the Co